Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2024-06-11 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
New Corporate Presentation
Regulatory Filings Classification · 1% confidence The document is a short announcement (3163 characters) released via RNS (Regulatory News Service). The key phrase is: 'N4 Pharma plc... is pleased to announce that a new Corporate Presentation has been published.' It directs the reader to a link to view the presentation. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report/presentation has been published, rather than containing the full content of that report, should be classified as a Report Publication Announcement (RPA). The content explicitly announces the publication of a 'Corporate Presentation'.
2024-06-11 English
Placing and Subscription to raise £630,000
Share Issue/Capital Change Classification · 1% confidence The document begins with an RNS Number (6293R) and is dated 07 June 2024. The content announces a 'Placing and Subscription to raise £630,000' and details the use of proceeds, broker warrants, and application for admission to trading on AIM. This is a formal announcement of a capital raising/financing activity. This fits the definition of 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the core subject matter is financing, making CAP more specific than the general RNS fallback.
2024-06-07 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 7228P' and contains the standard structure of a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. The date of the event and notification is May 23, 2024, and the content details the percentage change in voting rights (from 6.23% to 7.00%) for a specific person (DAVID FARRIER) in N4 Pharma PLC. This fits the definition for Major Shareholding Notification (MRQ).
2024-05-23 English
Result of AGM
AGM Information Classification · 1% confidence The document explicitly states it is announcing the 'Result of Annual General Meeting' and provides a table detailing the voting outcomes for various resolutions, including the reception of the annual report and the re-election of directors. This content directly corresponds to the information shared during or immediately following an AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document is short and serves as an announcement of the results, not the full AGM presentation itself, but AGM-R is the most specific category for this content.
2024-05-23 English
Posting of Annual Report & Notice of AGM
Report Publication Announcement Classification · 1% confidence The document is a regulatory announcement (indicated by the RNS Number and RNS distribution footer) from N4 Pharma PLC dated April 29, 2024. The title explicitly states "Posting of Annual Report & Notice of AGM". The text confirms that the Annual Report and Accounts for FY2023 and the Notice of AGM have been posted to shareholders and provides links where they can be accessed. Since the document itself is an announcement about the publication of the Annual Report and the AGM Notice, and it is short (3212 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the full 10-K or AGM-R document itself. It also mentions the AGM, which might suggest AGM-R, but the primary action described is the *posting* of the documents.
2024-04-29 English
N4 Pharma Webinar on SRI Collaboration
Regulatory Filings Classification · 1% confidence The document is a short announcement (3490 characters) distributed via RNS (RNS Number: 1231M) on April 26, 2024. It explicitly states that the company will provide a pre-recorded webinar on a specific date (May 7, 2024) regarding a recent collaboration agreement. It invites investors to view the webinar and submit questions. According to Rule 2, when a document is short and announces the publication or availability of other content (like a webinar or presentation), it should be classified as a Report Publication Announcement (RPA) if it's an announcement about a report/event, or RNS if it's a general regulatory notice. Since this is specifically announcing an upcoming investor event/presentation (webinar), RPA is the most precise fit, as it signals the upcoming release of investor-focused material. It is not the presentation itself (IP) or a transcript (CT).
2024-04-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.